NewAmsterdam Pharma Co N.V. Cash Flow Statement
NAMS / Health Care|5 years of annual SEC 10-K data (FY2021-FY2025)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 5 fiscal years. All figures from audited SEC 10-K filings.
NewAmsterdam Pharma Co N.V. used $148M in operating cash flow and negative free cash flow of $148M in FY2025.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 3.01 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Net Income | -$203.8M | -$241.6M | -$176.9M | -$22.6M | -$41.8M |
| Depreciation & Amortization | $220.0K | $113.0K | $49.0K | $9.0K | $5.0K |
| Operating Cash Flow | -$147.8M | -$158.6M | -$141.2M | $10.7M | -$29.5M |
| Capital Expenditures | $246.0K | $672.0K | $24.0K | $221.0K | $24.0K |
| Free Cash Flow | -$148.0M | -$159.2M | -$141.2M | $10.4M | -$29.5M |
| FCF Margin | - | - | - | 10.2% | - |